Optimal design for a study of butadiene toxicokinetics in humans

Toxicological Sciences

Volumn 49, Issue 2, 1999, Pages 213-224

  Bois, Frédéric Y ^a,d   Smith, Thomas J ^b   Gelman, Andrew ^c   Chang, Ho Yuan ^b   Smith, Andrew E ^b  

^a LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d INSERM   (France)

Author keywords

Butadiene population toxicokinetics; Human inhalation experiments; Markov chain Monte Carlo simulations; Optimal experimental design

Indexed keywords

1,3 BUTADIENE;

ARTICLE; BAYES THEOREM; COMPARTMENT MODEL; ENVIRONMENTAL EXPOSURE; HUMAN; HUMAN EXPERIMENT; METABOLIC CLEARANCE RATE; NORMAL HUMAN; POPULATION MODEL; SIMULATION; STATISTICAL MODEL; SYSTEM ANALYSIS; TOXICOKINETICS;

ADMINISTRATION, INHALATION; BUTADIENES; CARCINOGENS; HUMANS; MODELS, BIOLOGICAL; PHARMACOGENETICS; TIME FACTORS; TOXICOLOGY;

ANIMALIA;

EID: 0033001403     PISSN: 10966080     EISSN: None     Source Type: Journal    
DOI: 10.1093/toxsci/49.2.213     Document Type: Article

References (51)

1. Atkinson, A. C., Chaloner, K., Herzberg, A. M., and Juritz, J. (1993). Optimum experimental designs for properties of a compartmental model. Biometrics 49, 325-337.
2. Atkinson, A. C., and Donev, A. N. (1992). Optimum Experimental Designs. Oxford, New-York.
3. Beatty, D. A., and Piegorsch, W. W. (1997). Optimal statistical design for toxicokinetic studies. Stat. Methods Med. Res. 6, 359-376.
4. Bernardo, J. M., and Smith, A. F. M. (1994). Bayesian Theory. Wiley, New York.
5. Bois, F. Y., Gelman, A., Jiang, J., Maszle, D., Zeise, L., and Alexeef, G. (1996b). Population toxicokinetics of tetrachloroethylene. Arch. Toxicol. 70, 347-355.
6. Bois, F., Jackson, E., Pekari, K., and Smith, M. (1996a). Population toxicokinetics of benzene. Environ. Health Perspect. 104(suppl. 6), 1405-1411.
7. Bois, F. Y., and Maszle, D. (1997). MCSim: a simulation program. J. Stat. Software 2, http://www.stat.ucla.edu/journals/jss/v02/i09.
8. Bond, J. A., Himmelstein, M. W., and Medinsky, M. A. (1996). The use of toxicologic data in mechanistic risk assessment: 1,3-butadiene as a case study. Int. Arch. Occup. Environ. Health 68, 415-420.
9. Brunnemann, K. D., Kagan, M. R., Cox, J. E., and Hoffmann, D. (1990). Analysis of 1,3-butadiene and other selected gas-phase components in cigarette mainstream and sidestream smoke by gas chromatography-mass selective detection. Carcinogenesis 11, 1863-1868.
10. Burstein, A. H., Gal, P., and Forrest, A. (1997). Evaluation of a sparse sampling strategy for determining vancomycin pharmacokinetics in preterm neonates: application of optimal sampling theory. The Ann. Pharmacotherapy 31, 980-983.
11. California Environmental Protection Agency Air Resources Board (1992). Proposed Identification of 1,3-Butadiene as a Toxic Air Contaminant. Stationery Source Division, Sacramento, CA.
12. Carriere, V., Berthou, F., Baird, S., Belloc, C., Beaune, P., and de Waziers, I. (1996). Human cytochrome P450 2E1 (CYP2E1): from genotype to phenotype. Pharmacogenetics 6, 203-211.
13. Csanady, G. A., Guengerich, F. P., and Bond, J. A. (1992). Comparison of the biotransformation of 1,3-butadiene and its metabolite, butadiene monepoxide, by hepatic and pulmonary tissues from humans, rats, and mice. Carcinogenesis 13, 1143-1153.
14. D'Argenio, D. Z. (1981). Optimal sampling times for pharmacokinetic experiments. J. Pharmacok. Biopharm. 9, 739-756.
15. D'Argenio, D. Z. (1990). Incorporating prior parameter uncertainty in the design of sampling schedules for pharmacokinetic parameter estimation experiments. Math. Biosci. 99, 105-118.
16. Fajen, J. M., Roberts, D. R., Ungers, L. J. and Krishnan, E. R. (1990). Occupational exposure of workers to 1,3 butadiene. Environ. Health Perspect. 86, 11-18.
17. Fanning, E., Bois, F. Y., Rothman, N., Bechtold, B., Li, G., Hayes, R., and Smith, M. (1997). Population toxicokinetics of benzene and its metabolites. Toxicol. Appl. Pharmacol.(suppl.), 164.
18. Gelfand, A. E., and Smith, A. F. M. (1990). Sampling-based approaches to calculating marginal densities. J. Am. Stat. Assoc. 85, 398-409.
19. Gelman, A. (1992). Iterative and non-iterative simulation algorithms. Comput. Sci. Stat. 24, 433-438.
20. Gelman, A., Bois, F., and Jiang, J. (1996). Physiological pharmacokinetic analysis using population modeling and informative prior distributions. J. Am. Stat. Assoc. 91, 1400-1412.
21. Gelman, A., and Rubin, D. B. (1992). Inference from iterative simulation, using multiple sequences (with discussion). Stat. Sci. 7, 457-511.
22. Gelman, A., and Rubin, D. B. (1996). Markov chain Monte Carlo methods in biostatistics. Stat. Methods Med. Res. 5, 339-355.
23. Gilks, W. R., Richardson, S., and Spiegelhalter, D. J. (1996). Markov Chain Monte Carlo in Practice. Chapman & Hall, London.
24. Guengerich, F. P. (1996). In vitro techniques for studying drug metabolism. J. Pharmacok. Biopharm. 24, 521-533.
25. Hassett, C., Aicher, L., Sidhu, J. S., and Omiecinski, C. J. (1994). Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants. Hum. Mol. Genet. 3, 421-428.
26. International Agency for Research on Cancer (IARC) (1992). Occupational Exposures to Mists and Vapours from Strong Inorganic Acids and Other Industrial Chemicals. International Agency for Research on Cancer, Lyon, France.
27. Johanson, G. and Filser, J. G. (1996). PBPK model for butadiene metabolism to epoxides: Quantitative species differences in metabolism. Toxicology 113, 40-47.
28. Jonsson, F., Johanson, G., and Bois, F. Y. (1997). A new approach to estimate population variability in target dose based on genetic polymorphism data and PBTK modeling. Toxicol. Appl. Pharmacol.(suppl.), 34.
29. Kashuba, A. D. M., Ballow, C. H., and Forrest, A. (1996). Development and evaluation of a Bayesian pharmacokinetic estimator and optimal, sparse sampling strategies for ceftazidime. Antimicrob. Agents Chemother. 40, 1860-1865.
30. Mager, H., and Göller, G. (1998). Resampling methods in sparse sampling situations in preclinical pharmacokinetic studies. J. Pharm. Sci. 87, 372-378.
31. Mahmood, I. (1998). A limited sampling approach in pharmacokinetic studies: experience with the antiepilepsy drug tiagabine. Br.J. Clin. Pharmacol 38, 324-330.
32. Maszle, D., and Bois, F. Y. (1993). Program MCSim - User Manual. Available from the authors, or at ftp://sparky.berkeley.edu/pub/mcsim and http:// sparky.berkeley.edu/users/fbois.
33. Mentré, F., Mallet, A., and Baccar, D. (1997). Optimal design in random-effects regression models. Biometrika 84, 429-442.
34. Merlé, Y., and Mentré, F. (1995). Bayesian design criteria: computation, comparison, and application to a pharmacokinetic and a pharmacodynamic model. J. Pharmacokinet. Biopharm. 23, 101-125.
35. Müller, P., and Parmigiani, G. (1995). Optimal design via curve fitting of Monte Carlo experiments. J. Am. Stat. Assoc. 90, 1322-1330.
36. Mullins, J. A. (1990). Industrial emissions of 1,3-butadiene. Environ. Health Perspect. 86, 9-10.
37. National Research Council (NRC) (1994). Science and Judgement in Risk Assessment. National Academy Press, Washington, DC.
38. O'Keefe, A. E., and Ortman, G. O. (1966). Primary standards for trace gas analysis. Anal. Chem. 38, 760-763.
39. Pai, S. M., Fettner, S. H., Hajian, G., Cayen, M. N., and Batra, V. K. (1996). Characterization of AUCs from sparsely sampled populations in toxicology studies. Pharm. Res. 13, 1283-1290.
40. Palmer, J. L., and Müller, P. (1998). Bayesian optimal design in population models for haematologic data. Stat. Med. 17, 1613-1622.
41. Polson, N. G. (1992). On the expected amount of information from a non-linear model. J. Roy. Statist. Soc. B 54, 889-895.
42. Ramsey, J. C., and Andersen, M. (1984). A physiologically based description of the inhalation pharmacokinetics of styrene in rats and humans. Toxicol. Appl. Pharmacol. 73, 159-175.
43. Rappaport, S. M., Selvin, S., and Waters, M. A. (1987). Exposures to hydrocarbon components of gasoline in the petroleum industry. Appl. Ind. Hyg. 2, 148-154.
44. Reitz, R. H., MacDougal, J. N., Himmelstein, M. W., Nolan, R. J., and Schumann, A. M. (1988). Physiologically based pharmacokinetic modeling with methylchloroform: implications for interspecies, high dose/low dose, and dose route extrapolations. Toxicol. Appl. Pharmacol. 95, 185-199.
45. Smith, A. F. M., and Roberts, G. O. (1993). Bayesian computation via the Gibbs sampler and related Markov chain Monte Carlo methods. J. Roy. Statist. Soc. B 55, 3-23.
46. Tse, F. L. S., and Nedelman, J. R. (1996). Serial versus sparse sampling in toxicokinetic studies. Pharm. Res. 13, 1105-1108.
47. U.S. Environmental Protection Agency (1985). Mutagenticity and Carcinogenicity Assessment of 1,3-Butadiene, Publication No. EPA/600/8-85/004F. Office of Health Effects and Environmental Assessment, Washington, DC.
48. U.S. Environmental Protection Agency (1989). Revised Draft Final Report: Locating and Estimating Air Emissions for Sources of 1,3-Butadiene. Non-criteria Pollutant Programs Branch, Air Quality Management Division, Research Triangle Park, NC.
49. Wakefield, J. C. (1996). The Bayesian analysis of population pharmacokinetic models. J. Am. Stat. Assoc. 91, 62-75.
50. Wakefield, J. C., and Racine-Poon, A. (1995). An application of Bayesian population pharmacokinetic pharmacodynamic models to dose recommendation. Stat. Med. 14, 971-986.
51. Wakefield, J. C., Smith, A. F. M., Racine-Poon, A., and Gelfand, A. E. (1994). Bayesian analysis of linear and non-linear population models using the Gibbs sampler. Appl. Statist. - J. Roy. Statist. Soc. C 43, 201-221.